Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave-February 2024-www.financetom.com

Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave

Mar 14, 2024 10:03 AM

12:43 PM EDT, 03/14/2024 (MT Newswires) -- Cullinan Oncology ( CGEM ) said Thursday that its Chief Financial Officer Jeffrey Trigilio is leaving the company, effective March 29.

Trigilio agreed to support Cullinan through the transition period after his departure, according to the company.

Price: 16.88, Change: -0.10, Percent Change: -0.59

Previous page： Rexford Industrial Realty Buys $1 Billion Portfolio of Industrial Properties in Southern California from Blackstone Next page： Metalla Royalty & Streaming 2023 Loss Narrows on Revenue Gains

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Rexford Industrial Realty Buys $1 Billion Portfolio of Industrial Properties in Southern California from Blackstone

Mar 28, 2024

04:42 PM EDT, 03/28/2024 (MT Newswires) -- Rexford Industrial Realty ( REXR ) has acquired more than 3 million square feet of industrial properties in southern California through a series of transactions with alternative asset manager Blackstone for a combined $1 billion, the real estate investment trust said on Thursday. The acquired portfolio includes 48 properties in Los Angeles and...

Metalla Royalty & Streaming 2023 Loss Narrows on Revenue Gains

Mar 28, 2024

04:40 PM EDT, 03/28/2024 (MT Newswires) -- Metalla Royalty & Streaming ( MTA ) on Thursday said its 2023 loss narrowed on higher revenue. The company said it lost US$5.84 million, or US$0.11 per share, over the year, compared with a loss of US$10.93 million, or US$0.24, in 2022. Revenue rose 90% to US$4.6 million from US$2.41 million. 2023 was...

Bristol-Myers Squibb's Phase 3 Trial of Crohn's Disease Treatment Fails to Meet Primary Endpoint

Mar 28, 2024

04:39 PM EDT, 03/28/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said late Thursday an initial analysis of data showed that the first of two induction studies in a phase 3 trial of Zeposia in adults with Crohn's disease didn't meet the primary endpoint of clinical remission at week 12. The company said it plans to finalize a full...

US FDA extends review of Applied Therapeutics' genetic disease drug

Mar 28, 2024

March 28 (Reuters) - The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' ( APLT ) experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday. The health regulator will now give its decision by Nov. 28, 2024, compared with its previous action date of Aug. 28. ...